Genentech Announces Plans to Expand California Biologics Manufacturing Facilities

  Genentech Announces Plans to Expand California Biologics Manufacturing
  Facilities

       --- Investment to Bring More Than 250 New Jobs to the State ---

Business Wire

SOUTH SAN FRANCISCO, Calif. -- October 14, 2013

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today
announced plans to invest more than $285 million for the expansion of its
biologics manufacturing facilities in Vacaville and Oceanside, California.
“This investment and expansion will result in the addition of more than 250
new jobs at the Vacaville and Oceanside facilities over the next four years,
bringing the total number of Genentech manufacturing jobs in California to
close to 3,000,” said Ian Clark, Chief Executive Officer of Genentech. The
company currently employs approximately 10,000 people in the state.

These investments in Genentech’s biologics manufacturing network will enable
the hiring of hundreds of skilled workers, ranging from technicians to
scientists and engineers. “California has always had an impressive skilled
workforce that has allowed Genentech to hire diverse and talented individuals
in various disciplines,” Clark said. “In recent years California has made
great strides toward improving the business environment for life sciences
innovation and incentivizing manufacturing. We are committed to working with
the state to continue this positive progress and make California an even
better place to grow the industry.”

Genentech’s United States manufacturing network spans three locations in
California – South San Francisco, Vacaville, and Oceanside – and Hillsboro,
Oregon, producing medicines intended for the treatment of a wide range of
diseases including cancer, rheumatoid arthritis, and asthma. When the
expansion is complete, Genentech’s Vacaville facility will not only be the
largest producer of biologic medicines for the Roche Group but also the
largest biotech manufacturing facility in the world.

About Biologics and Their Manufacturing

Biologic medicines are large molecules that are created by biological
processes, rather than being chemically synthesized, and are typically
administered via injection or intravenously. Roche is a world leader in
biologic medicine manufacturing, with long-standing expertise in biotech
manufacturing and has the largest biotech production capacity of any company
worldwide.

The biologics unit at Roche consists of several manufacturing sites in North
America, Europe and Asia, which work as a closely aligned network focused on
all aspects of biologic medicine manufacturing and supply. The manufacturing
of biologic medicines consists of two operations, the production of drug
substance and drug product. The production of drug substance uses genetically
modified cells to serve as mini-factories that can manufacture the appropriate
proteins. The production of drug product includes the final formulation of the
medicine into a sterile liquid or powder that can be filled into a vial,
syringe or device, which is then packaged for worldwide distribution.

About Genentech

Founded more than 35 years ago, Genentech is a leading biotechnology company
that discovers, develops, manufactures and commercializes medicines to treat
patients with serious or life-threatening medical conditions. The company, a
member of the Roche Group, has headquarters in South San Francisco,
California. For additional information about the company, please visit
http://www.gene.com.

Contact:

Genentech
Robin Snyder, 650-467-6800 (Media)
Thomas Kudsk Larsen, 650-467-2016 (Investors)
Karl Mahler, 011 41 61 687 8503 (Investors)